Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Palobiofarma (Details)

v3.20.2
Royalty Purchase Agreements - Palobiofarma (Details)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 26, 2019
USD ($)
item
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Agreements        
Payments to acquire milestones and royalties     $ 19,300  
Proceeds from issuance of long-term debt     $ 9,500  
Long-term royalty receivables   $ 34,375   $ 34,375 [1]
Impairment of long-term royalty receivable   0   $ 0
Increase (decrease) of long-term royalty receivable   0    
Royalty Purchase Agreement | Palobiofarma, S.L.        
Agreements        
Number of drug candidates | item 6      
Payments to acquire milestones and royalties $ 10,000      
Long-term royalty receivables 10,000      
Impairment of long-term royalty receivable   $ 0    
Royalty Purchase Agreement | Palobiofarma, S.L. | Silicon Valley Bank Loans        
Agreements        
Proceeds from issuance of long-term debt $ 5,000      
[1] The consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.